{"type":"trials","record":{"id":42127,"source_id":"clinicaltrials-gov","external_id":"NCT02914639","title":"Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)","brief_summary":"The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).","overall_status":"Completed","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"OcuTerra Therapeutics, Inc.","enrollment":44,"countries":["United States"],"start_date":"2016-10-05","completion_date":"2017-06-26","last_update_date":"2023-06-07","source_url":"https://clinicaltrials.gov/study/NCT02914639","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"OcuTerra Therapeutics, Inc.","interventions":["SF0166 Topical Ophthalmic Solution"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Subjects With No Cells Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline, Week 2, W…","Number of Subjects With Flare Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline, Week 2, Week…","Number of Subjects With Absence of Hyphema Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline,…","Number of Subjects With Absence of Bulbar Conjunctival Injection Observed Following Slit Lamp Examination From Baseline…","Number of Subjects With Absence of Erythema Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline…","Number of Subjects With Absence of Edema Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline, W…","Number of Subjects With Any Lens Opacity Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline, W…","Number of Subjects With Abnormal Findings in Optic Nerve Following Fundus Examination From Baseline to Week 8 — Baselin…","Number of Subjects With Abnormal Findings in Vitreous Following Fundus Examination From Baseline to Week 8 — Baseline,…","Number of Subjects With Abnormal Findings in Fundus Following Fundus Examination From Baseline to Week 8 — Baseline, We…","Number of Subjects With Abnormal Findings in Macula/Choroid Following Fundus Examination From Baseline to Week 8 — Base…","Number of Subjects With Abnormal Findings in Vessels Following Fundus Examination From Baseline to Week 8 — Baseline, W…","Cup:Disc Ratio of Subjects Following Fundus Examination From Baseline to Week 8 — Baseline, Week 2, Week 4, Week 6 and…","Number of Subjects With Abnormal Findings Following A Fluorescein Angiogram at Week 4 Compared to Baseline — Baseline a…","Change in Intraocular Pressure From Baseline to Week 8 — Week 2, Week 4, Week 6 and Week 8","Change in Study Eye Central Retinal Thickness (CRT) From Baseline (Day 0) to Week 8 — Week 2, Week 4, Week 6 and Week 8","Change in Best-corrected Visual Acuity (BCVA) From Baseline (Day 0) at Week 4 and Week 8 — Week 2, Week 4, Week 6, and…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":true},"controlled_terms":["Age-Related Macular Degeneration","SF0166 Topical Ophthalmic Solution"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02914639","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2016-10-05 to 2017-06-26","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.924Z","intervention":["SF0166 Topical Ophthalmic Solution"],"participants":44,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Subjects With No Cells Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline, Week 2, W…","Number of Subjects With Flare Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline, Week 2, Week…","Number of Subjects With Absence of Hyphema Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline,…","Number of Subjects With Absence of Bulbar Conjunctival Injection Observed Following Slit Lamp Examination From Baseline…","Number of Subjects With Absence of Erythema Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline…","Number of Subjects With Absence of Edema Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline, W…","Number of Subjects With Any Lens Opacity Observed Following Slit Lamp Examination From Baseline to Week 8 — Baseline, W…","Number of Subjects With Abnormal Findings in Optic Nerve Following Fundus Examination From Baseline to Week 8 — Baselin…","Number of Subjects With Abnormal Findings in Vitreous Following Fundus Examination From Baseline to Week 8 — Baseline,…","Number of Subjects With Abnormal Findings in Fundus Following Fundus Examination From Baseline to Week 8 — Baseline, We…","Number of Subjects With Abnormal Findings in Macula/Choroid Following Fundus Examination From Baseline to Week 8 — Base…","Number of Subjects With Abnormal Findings in Vessels Following Fundus Examination From Baseline to Week 8 — Baseline, W…","Cup:Disc Ratio of Subjects Following Fundus Examination From Baseline to Week 8 — Baseline, Week 2, Week 4, Week 6 and…","Number of Subjects With Abnormal Findings Following A Fluorescein Angiogram at Week 4 Compared to Baseline — Baseline a…","Change in Intraocular Pressure From Baseline to Week 8 — Week 2, Week 4, Week 6 and Week 8","Change in Study Eye Central Retinal Thickness (CRT) From Baseline (Day 0) to Week 8 — Week 2, Week 4, Week 6 and Week 8","Change in Best-corrected Visual Acuity (BCVA) From Baseline (Day 0) at Week 4 and Week 8 — Week 2, Week 4, Week 6, and…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42127","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}